Ziopharm Oncology says investigational new drug application for clinical trial in solid tumors to evaluate T-cell receptor (TCR) T-cell therapy utilizing its Sleeping Beauty platform received clearance from FDA.
- IND was filed by National Cancer Institute, which is partnered with Ziopharm in a cooperative research and development agreement
Link to Statement: Ziopharm Oncology Announces FDA Clearance of IND for Sleeping Beauty TCR-T Cell Therapy Trial at NCI
©2019 Bloomberg L.P. All rights reserved. Used with permission
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.